RCM Technologies (NASDAQ: RCMT) reported that Michael Saks, the companys division president for Healthcare Services, sold 5,000 shares of common stock in two transactions on April 15 and April 16, 2026, according to a Form 4 filed with the Securities and Exchange Commission.
The two trades were executed at $30.00 per share, producing gross proceeds of $150,000. On April 15, Saks sold 136 shares; on April 16, he sold 4,864 shares. Following these dispositions, the filing shows Saks retains direct ownership of 104,814 shares of RCM Technologies common stock.
The sales were made under a previously established plan dated December 6, 2024, which the filing notes was intended to satisfy Rule 10b5-1 requirements. The filing does not provide additional commentary on Saks motivations beyond the existence of that plan.
At the time the filing was noted, RCMT shares were trading at $31.76, modestly above the $30.00 execution price used for the transactions and close to a reported 52-week high of $30.50. Over the past 12 months the stock has returned approximately 89%.
The filing and accompanying analysis reference valuation metrics from InvestingPro. That analysis places a Fair Value for RCMT at $41.28 and reports a PEG ratio of 0.48, figures that imply a valuation materially higher than the price at which the shares were sold.
The Form 4 does not add further explanation about the timing of the trades beyond the Rule 10b5-1 plan, nor does it alter the disclosed remaining ownership stake held directly by Saks. Investors and market observers relying on the filing have the discrete data points needed to assess the transaction: the specific share counts on each date, the per-share price, the residual ownership after the sale, and the presence of a prearranged sales plan.
Context and data from the filing
- Shares sold: 5,000 (136 on April 15; 4,864 on April 16, 2026)
- Price per share: $30.00
- Total proceeds: $150,000
- Remaining direct ownership: 104,814 shares
- Plan date: December 6, 2024 (Rule 10b5-1 plan)
- Market reference points: trading price $31.76; 52-week high $30.50; 12-month return ~89%
- Valuation metrics cited: Fair Value $41.28; PEG ratio 0.48 (InvestingPro)
This filing provides the formal record of the transactions and the attendant data points that investors use to monitor insider activity, ownership levels, and how those actions align with prevailing market prices and third-party valuation estimates.